Lower CVD incidence is reported in Asian populations consuming soya-containing food. As polymorphonuclear leukocytes (PMN) are involved in the risk of CVD, we investigated the modulatory effect of soya isoflavones on several PMN functions and their molecular mechanisms in vitro. PMN, isolated from blood from healthy subjects, were tested upon activation with 1 mM-n-formyl-methyl-leucyl-phenylalanine (fMLP) for superoxide anion production (ferric cytochrome c reduction) and released elastase (chromogenic test). PMN homotypic aggregates stimulated by fMLP or P-selectin in dynamic conditions were detected by optical microscopy. PMN, mixed with thrombin-activated, washed platelets, formed cell aggregates, measured by flow cytometry. Phosphorylation of Pyk2, a focal adhesion kinase, was studied by immunoprecipitation and immunoblotting with specific antibodies. Genistein, daidzein and equol inhibited superoxide anion production (IC 50 0·25 (SEM 0·1), 21·0 (SEM 4·2) and 13·0 (SEM 2·8) mM, respectively); the release of elastase was prevented by genistein (IC 50 63 (SEM 17) mM). PMN homotypic aggregates, stimulated by fMLP, were significantly reduced (24 (SEM 12) and 51 (SEM 14) % of control) by 100 mM genistein and equol. P-selectin-induced aggregates were reduced to 19 (SEM 6), 44 (SEM 10) and 28 (SEM 9) % of control by 100 mM genistein, daidzein and equol, respectively. Genistein, daidzein and equol also significantly reduced mixed platelet-PMN aggregates (IC 50 4·0 (SEM 0·9), 57 (SEM 6) and 66 (SEM 23) mM, respectively). In PMN challenged by fMLP or P-selectin, activation of Pyk2 was prevented by isoflavones. The cardioprotective effect of soya-containing food might be linked to reduction of PMN activation and PMN-platelet interaction, novel targets for the biological effects of soya isoflavones.
. Activated leukocytes have been reported in the systemic circulation of patients after myocardial infarction 4 or coronary angioplasty 5 . Platelet/leukocyte interactions and leukocyte incorporation into and/or on to thrombi have been observed in different experimental models. While thrombocytopenia decreases leukocyte recruitment after vascular injury in a porcine model 6 , platelet accumulation in experimental myocardial infarction is reduced by PMN depletion 7 . In animal models of myocardial infarction, PMN depletion, pharmacological suppression of PMN activation, as well as inhibition of PMN-endothelial cell interactions, reduced the extent of acute tissue injury and mortality following ischaemia and reperfusion 8, 9 . Activated PMN can be responsible for several manifestations of IHD due to their ability to produce and release reactive oxygen species, leukotriens and proteolytic enzymes, which can directly induce vascular damage and/or influence the activation state of platelets and endothelial cells 10 . Many common diseases are diet-related and could benefit from diets rich in compounds that down regulate PMN function. Asian populations consuming soya-containing food have reportedly a lower incidence of CVD than people from Western countries 11 . Among soya components, the isoflavones genistin and daidzin are bound to glucose and, when ingested by man, are enzymatically cleaved by the gut microflora to their respective active forms: genistein; daidzein 12 . Daidzein is then converted to equol, another isoflavon. Soya isoflavones are also referred to as phyto-oestrogens because of the presence of a phenolic ring, which enables them to bind to oestrogen receptors in human individuals, but their mechanism of action is not exclusively hormonal, including antioxidant, antiproliferative and antiangiogenic activities 13 .
The aim of the present study was to investigate the capacity of soya isoflavones to modulate in vitro PMN function, as well as homotypic and heterotypic PMN interactions.
Experimental methods

Materials
Genistein, daidzein and equol were purchased from Extrasynthèse (Genay, France). HEPES, PGE1, ethylene glycol-bis (b-aminoethyl ether)-N,N,N 0 ,N 0 -tetraacetic acid (EGTA), 2 0 ,7 0 -bis-(2-carboxyethyl)-5(6)-carboxy-fluorescein, cytochalasin B, ferric cytochrome c, n-formyl-methyl-leucyl-phenylalanine (fMLP), phorbol-myristate-acetate (PMA), fluorescein isothiocyanote (FITC)-conjugated anti-Mac-1 mouse monoclonal antibody (MoAb), thrombin from human plasma (2000 National Institute of Health U/mg protein), N-succinyl-AlaAla-Val-p-nitroanilide were from Sigma Chemical Co. (St. Louis, MO, USA). Dextran T500 and Ficoll Hypaque were from Pharmacia Fine Chemicals (Uppsala, Sweden). Hydroxyetidine was from Molecular Probes Europe (Leiden, The Netherlands), paraformaldehyde (PFA) from Fluka (Milano, Italy). Soluble human P-selectin was purified from fresh platelet lysates by immunoaffinity using the anti-P-selectin MoAb WAPS 12·2, purified from mouse ascites or hybridoma cell (American Tissue Type Colture Collection, Manassas, VA, USA) supernatants, using protein G-sepharose affinity columns. The anti-phosphotyrosine PY99 and the anti-Pyk2 (C19) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The enhanced Chemi-Luminescence Western blotting system (ECL-kit) was from Amersham Life Science (Little Chalfont, Buckinghamshire, UK). Reagents for electrophoresis and Western blot analysis were pure grade. fMLP and PMA were dissolved in dimethyl sulphoxide (DMSO), stored at 2 208C and diluted in isotonic saline just before use. Thrombin was dissolved in saline at concentrations of 50 U/ml and stored at 2 208C until use. Soya isoflavones were dissolved in DMSO just before use. The final concentration of DMSO in samples was always #0·5 % (v/v). In each experiment, the control group was tested in the presence of an equivalent dilution of DMSO.
Preparation of polymorphonuclear leukocytes and platelets
Human blood was collected from healthy volunteers who had not received any medication for at least 2 weeks. Nine parts of blood were anticoagulated with one part of 3·8 % trisodium citrate. Cells were isolated from whole blood using standard procedures performed at room temperature 14 . Briefly, platelet-rich plasma was prepared by centrifuging whole blood at 250 g for 25 min. PMN were isolated from the remaining blood by dextran sedimentation, followed by Ficoll-Hypaque gradient and hypotonic lysis of erythrocytes. PMN were washed and resuspended in HEPES-Tyrode (HT) buffer (129 mM-NaCl, 9·9 mM-NaHCO 3 , 2·8 mM-KCl, 0·8 mM-KH2PO 4 , 5·6 mM-dextrose, 10 mM-HEPES, in bidistilled water) added with 1 mM-CaCl 2 and 1 mM-MgCl 2 .
PMN suspensions contained 95 % PMN and an average of one platelet per thirty PMN.
For adhesion experiments, PMN were stained with the vital red fluorescent dye hydroxyetidine (20 mg/ml per 5 £ 10 7 PMN/ml) for 30 min at 48C. Platelets were loaded with the green fluorescent dye 2 0 ,7 0 -bis-(2-carboxyethyl)-5(6)-carboxyfluorescein (BCECF), by incubating platelet-rich plasma with 2 mg/ml of its acetoxymethyl ester (2 0 ,7 0 -bis-(2-carboxyethyl)-5(6)-carboxyfluorescein) for 30 min at 378C. After two washes in the presence of 2 mM-PGE1 and 5 mM-EGTA, the BCECF-loaded platelets were resuspended in HT buffer added with 1 mM-CaCl 2 and 1 mM-MgCl 2 , at 1 £ 10 9 platelets/ml. Platelets were stimulated with thrombin 0·5 U/ml for 2 min at room temperature and fixed with one volume of 2 % PFA at room temperature for 1 h. After fixation, platelets were washed and resuspended in the same medium with 1 mM-CaCl 2 and 1 mM-MgCl 2 , at 1 £ 10 8 cells/ml.
Experimental conditions
All the experiments (except superoxide anion production) have been performed in the following experimental conditions (standard conditions). Cells were incubated in a final volume of 500 ml, in siliconized glass tubes (internal diameter 6 mm; ChronoLog, Mascia Brunelli, Milano, Italy) and the tubes were placed in an aggregometer (Platelet Ionized Calcium Aggregometer, PICA; ChronoLog) at 378C with stirring at 1000 rpm. Although the shear rate produced by this stirring speed cannot be precisely quantified, it should be approximately 250 per s 15 .
Measurement of superoxide anion production
Superoxide anion production was determined by measuring the reduction of ferric cytochrome c 16 . PMN (1 £ 10 7 /ml), in the presence of 2·5 mg/ml cytochalasin B and 20 nmol ferric cytochrome c, were pre-incubated in a 96-well microtitre plate with DMSO (control) or with different concentrations of soya isoflavones for 5 min at room temperature, before stimulation with 1 mM-fMLP or 100 nM-PMA for 40 min. Basal superoxide anion production from unstimulated PMN was assessed in samples incubated with DMSO, cytochalasin B and ferric cytochrome c, but without fMLP. Thereafter, absorbance was measured simultaneously at 550 and 540 nm with Multiskan spectrophotometer (Titertek Labsystems, Basingstoke, UK) and the resulting ratio expressed as nanomoles of ferric cytochrome c reduced by 10 6 PMN in 40 min.
Polymorphonuclear leukocyte elastase activity assay
Elastase activity, released in supernatants from PMN, was assayed spectrophotometrically by monitoring the rate of release of p-nitroanilide from the specific chromogenic substrate N-succinyl-Ala-Ala-Val-p-nitroanilide at 410 nm in 5-min kinetics 14 . PMN were pre-incubated with DMSO or different concentrations of soya isoflavones for 5 min at room temperature, in the presence of cytochalasin B (2·5 mg/ ml), before stimulation with 1 mM-fMLP; after 3 min samples were centrifuged and supernatants used to measure enzyme release. Elastase concentration was extrapolated from a standard curve of known concentrations of purified human elastase. Results are presented as % of controls.
Polymorphonuclear leukocyte aggregation experiments
Samples of washed PMN (500 ml, 1 £ 10 7 /ml) in HT buffer, containing CaCl 2 and MgCl 2 (1 mM each), were pre-incubated with DMSO (control) or different concentrations of soya isoflavones for 5 min at room temperature. Cell suspensions were stimulated (1 mM-fMLP or 25 mg/ml soluble P-selectin), for 3 min in standard conditions. Aliquots of the PMN suspension (50 ml) were then fixed with PFA (1 % final concentration) and the single, non-aggregated PMN were counted under contrast light microscopy. The number of single PMN counted before and after stimulation was used to calculate the percentage of aggregated PMN. Results are presented as % of control.
Double colour flow cytometric assay of polymorphonuclear leukocyte-platelet adhesion A previously described methodology has been used 17, 18 . Briefly, hydroxyetidine-loaded PMN (1 £ 10 7 /ml) were preincubated with DMSO (control) or soya isoflavones for 5 min at room temperature, then they were placed to interact with an equal volume of BCECF-loaded, thrombin-activated fixed platelets (1 £ 10 8 /ml), under stirring at 1000 rpm, at 378C, in the aggregometer. Cell interaction was stopped after 1 min with one volume of 2 % PFA and samples kept at 48C in the dark and analysed within 1 h by FACStar flow cytometer (Becton Dickinson, Milano, Italy) with an argonion laser operated at 400 mW output power.
PMN were identified on the basis of forward and side scatter alone or in combination with the specific red fluorescent marker. Gating on events identified as PMN was performed in order to exclude single platelets. For each experiment, the threshold of adhesion was set on the green fluorescence scale by use of a sample of mixed cells in the presence of 10 mM-EGTA. Platelet adhesion was quantified by evaluating the relative number of platelets bound to 100 PMN (platelets/100 PMN), as described 17 . Results are presented as % of control.
Flow cytometric analysis of Mac-1 expression on polymorphonuclear leukocyte surface Samples of washed PMN (1 £ 10 7 /ml) in HT buffer containing CaCl 2 and MgCl 2 (1 mM each) were incubated with DMSO (control) or with different concentrations of soya isoflavones for 5 min at room temperature and therefore stimulated for 3 min with 1 mM-fMLP, in standard conditions. After stimulation, 100 ml sample aliquots were incubated with a FITCconjugated anti-Mac-1 MoAb, for 30 min at 48C. Incubation was blocked by adding 1 ml ice-cold HT buffer. PMN fluorescence was analysed by a FACStar flow cytometer as previously described 17 . Acquisition and processing of data from 5000 cells was carried out with a Consort 30 Program (Becton Dickinson) on a Hewlett Packard 300 computer. Labelling with anti-Mac-1 MoAb was evaluated as mean fluorescence intensity in arbitrary units.
Pyk2 tyrosine phosphorylation
PMN, pretreated with 5 mM-di-isopropyl fluorophosphates to inhibit intracellular proteases, were incubated with DMSO or soya isoflavones for 5 min before stimulation with 1 mM-fMLP or 25 mg/ml soluble P-selectin. PMN were stirred at 1000 rpm for 3 min at 378C and then lysed in reducing Laemmli's buffer containing protease and phosphatase inhibitors. The samples were boiled for 10 min and diluted 1:20 with 1 % Triton X-100 lysis buffer (1 % Triton X-100, 150 mMNaCl and 25 mM-Tris-Hcl, pH 7·4) containing protease and phosphatase inhibitors. After pre-clearing with Protein G-Sepharose, the samples were incubated at 48C overnight with 10 mg/ml anti-Pyk2 antibody and Protein G-Sepharose. The immunoprecipitates were analysed by immunoblotting with either 0·1 mg/ml anti-Pyk2 (which recognizes whole Pyk2 protein) or PY99 (which recognizes phosphorylated tyrosines) antibody 19, 20 .
Statistical analysis
Data are presented as means with their standard errors of the mean. One-way ANOVA was followed by Dunnett's multiple comparison test; P values of 0·05 or lower were considered significant. IC 50 values (i.e. the concentration of compounds required to produce 50 % of inhibition of maximal response) were calculated using a Mac Allfit computer program.
Results
Effect on superoxide anion production
Superoxide anions produced by 1 £ 10 6 PMN within 40 min resulted in the reduction of 0·25 (SEM 0·08) nmol cytochrome c. This amount rose to 11·0 (SEM 1·4) and 19·1 (SEM 1·3) upon cell stimulation with 1 mM-fMLP or 100 nM-PMA, respectively (n 3).
Genistein, daidzein and equol inhibited fMLP-induced production of superoxide anions in a concentration-dependent manner with IC 50 0·25 (SEM 0·1), 21·0 (SEM 4·2) and 13·0 (SEM 2·8) mM, respectively (Fig. 1) . The amounts of cytochrome c reduced by superoxide anions from fMLPstimulated PMN in the presence of 100 mM genistein, daidzein or equol were 0·6 (SEM 0·03), 2·0 (SEM 0·07) and 2·1 (SEM 0·2) nmol, respectively. None of the isoflavones inhibited PMA-induced production of superoxide anions. In fact, the amounts of cytochrome c reduced by superoxide anions from PMA-stimulated PMN in the presence of 100 mM genistein, daidzein or equol were 17·0 (SEM 1·7), 17·8 (SEM 2·5) and 16·2 (SEM 2·0) nmol, respectively (not significantly different from 19·1 (SEM 1·3) nmol in control samples, n 3).
Effect on elastase release
Genistein (5 -100 mM) inhibited the release of elastase from PMN stimulated for 3 min with 1 mM-fMLP in a concentration-dependent manner, with an IC 50 63 (SEM 17) mM (n 3; P, 0·05 both at 50 and 100 mM); daidzein slightly affected this process at the highest concentration (88 (SEM 4) % of control, at 100 mM, n 3), while equol was ineffective (data not shown).
Effect on homotypic polymorphonuclear leukocyte adhesion induced by n-formyl-methyl-leucyl-phenylalanine or soluble P-selectin PMN stimulation by 1 mM-fMLP induced aggregate formation, where 66 (SEM 12) % of PMN were recruited (n 5). Aggregated PMN was reduced to 24 (SEM 12) % and 51 (SEM 14) % of PMN recruited by 100 mM genistein and equol, respectively ( Fig. 2(a) , reporting values as percentage of controls, in the absence of isoflavones). The inhibition by daidzein was not statistically significant.
Stimulation for 3 min with P-selectin induced the formation of aggregates, where 63 (SEM 10) % of PMN were recruited (n 6). Genistein, daidzein or equol inhibited P-selectin-induced PMN aggregation in a concentrationdependent manner (Fig. 2(b) , reporting values as percentage of controls, in the absence of isoflavones). The IC 50 for genistein and equol were 7·5 (SEM 1·5) and 85 (SEM 22) mM, respectively (n 6). Aggregated PMN was reduced from 63 (SEM 10) % to 19 (SEM 6), 44 (SEM 10) and 28 (SEM 9) % after pre-incubation with 100 mM genistein, daidzein, or equol, respectively. 
Effect on polymorphonuclear leukocyte-platelet adhesion
Activated PMN adhered to stimulated platelets in a timedependent manner, reaching a maximum at 1 min. At this time, in DMSO-treated samples (control), the percentage of PMN positive for platelet fluorescence marker (%(þ)PMN) was 58 (SEM 12) % (n 4) and the number of platelets adherent to 100 PMN (platelets/100 PMN) was 464 (SEM 161) (n 4). Genistein, daidzein and equol reduced in a concentrationdependent manner the ability of PMN to adhere to thrombin-activated platelets with IC 50 4·0 (SEM 0·9), 47 (SEM 6) and 66 (SEM 23) mM, respectively, when considering the number of platelets carried by 100 PMN (n 4, Fig. 3 ). The percentage of (þ)PMN was reduced to 16·0 (SEM 3·4), 32 (SEM 7), 36 (SEM 13) and the number of platelets/100 PMN to 38 (SEM 5), 122 (SEM 31) and 166 (SEM 72), after pre-incubation of PMN with 100 mM genistein, daidzein, and equol, respectively.
Effect on the expression of the b2-integrin Mac-1 induced by n-formyl-methyl-leucyl-phenylalanine on polymorphonuclear leukocyte surface
The mean fluorescence (arbitrary units) of PMN population increased from a basal value of 18 (SEM 1) to 59 (SEM 6) (n 4) upon stimulation with 1 mM-fMLP.
Preincubation of PMN with genistein, daidzein or equol, at the highest concentration tested (100 mM), did not significantly modify basal or fMLP-induced Mac-1 expression (data not shown).
Effect on protein Pyk2 tyrosine phosphorylation
We and others have identified the tyrosine kinase Pyk2 as a possible mediator of oxidative burst and of b2-integrin adhesive function in PMN 20 -22 . Therefore, we analysed the effect of soya isoflavones on Pyk2 phosphorylation in PMN challenged by fMLP or P-selectin.
The level of Pyk2 phosphorylation in fMLP-stimulated PMN was reduced by preincubation with 100 mM genistein, daidzein or equol (Fig. 4(a) ). Similar results were obtained when PMN were stimulated with P-selectin (Fig. 4(b) ).
Discussion
In the present study, we show that the soya isoflavones genistein, daidzein and equol inhibit at a different extent several PMN functions contributing to the pathogenesis and evolution of CHD.
The concentrations of soya isoflavones required for the in vitro inhibitory activities described in the present paper are higher than those reached in plasma of human subjects and experimental animals after short-term as well as prolonged administration. However, isoflavones may accumulate in tissues, reaching there concentrations much higher than those measured in serum 23 . Regular consumption of soya products, together with other polyphenol-rich foods, such as fruits and vegetables, might further increase isoflavone concentrations within the blood circulation and/or relevant tissues.
In recent years, evidence has been presented on the beneficial effect of soya isoflavones on CVD risk and mortality 24 . The mechanisms by which these compounds may prevent or reduce atherosclerosis include improvement in lipid profile 25 , antioxidant activity 26 , vascular relaxation 27 and inhibition of platelet aggregation 28 . All three isoflavones, genistein in particular, exerted a potent antioxidant effect on superoxide anions produced by fMLP-stimulated PMN. Toxic oxygen metabolites, which mediate cellular injury by initiating membrane lipid peroxidation, induce endothelial cell damage, activation of both endothelial cells and platelets and alteration of vascular permeability 29, 30 . Isoflavones exert antioxidant effects in vitro and in vivo. Human consumption of soya containing naturally occurring phyto-oestrogens reduced lipid peroxidation in vivo and increased resistance of LDL to oxidation 31 . Genistein increases activity of antioxidant enzymes, such as catalase, superoxide dismutase, glutathione peroxidase and glutathione reductase 32 . The present results confirm the antioxidant properties of soya isoflavones and show that they also inhibit, at very low concentrations, the production of superoxide anions by fMLP-stimulated PMN, but not by PMA, the direct protein kinase C activator. This indicates that the antioxidant effect is not due to a scavenger action of the compounds, but is instead mediated by inhibition of signalling step(s), necessary for NADPH oxidase activation, which are upstream to or independent from protein kinase C. This also might explain the different effect of genistein and daidzein and equol on fMLP-induced superoxide anion production.
At higher concentrations, genistein also inhibited the release of elastase from PMN activated by fMLP. Proteolytic enzymes released from neutrophil cytoplasmic granules are responsible for various effects leading to vascular damage. Elastase causes detachment or lysis of endothelial cells and degradation of subendothelial matrices and stimulates endothelial cell secretion of growth factors for smooth muscle cells 33 . As increased plasma levels of elastase were reported in acute IHD and after coronary angioplasty 34, 35 , proteases released Localization of PMN at sites of inflammatory reactions or thrombus formation is mediated by adhesion receptors of the b2 integrin family, such as the CD11b-CD18 Mac-1. These molecules are constitutively expressed on PMN surface and also stored in secretory granules. Upon inflammatory activation, Mac-1 is rapidly translocated from the intracellular pools to the cell surface and, in parallel, conformational changes within the molecule allow competent binding to its counter receptors on PMN (homotypic cell adhesion), as well as on platelets and on vascular cell surface (heterotypic cell adhesion) 36 . In particular, PMN adhesion to platelets is coordinated by an adhesion cascade in which the glycoprotein P-selectin expressed on the surface of activated platelets binds to P-selectin glycoprotein ligand-1 on PMN to promote the initial tethering of the cells, followed by subsequent firm adhesion mediated by Mac-1 binding to its counter receptors on platelets.
In our system, genistein, equol and daidzein prevented PMN homotypic aggregation induced either by the chemotactic peptide fMLP or by soluble human P-selectin, as well as the formation of PMN/platelet aggregates in mixed cell suspension. However, they did not impair Mac-1 translocation from intracellular stores to PMN surface, indicating that they may interfere with the intracellular signalling that allows competent binding of Mac-1 to its counter receptors, which is necessary for an efficient cell -cell adhesion to occur. In agreement with the present data, soya isoflavones (genistein, daizein and equol or sera from soya diet-fed rats) inhibited monocyte adhesion to endothelial cell specific CD54, by blocking the affinity regulation of CD11a 37 . Isoflavones, especially genistein, have been shown to inhibit cellular tyrosine kinases 38 ; however, the specific targets that may explain the biological effects of these compounds remain largely unknown.
Previous studies from our laboratory showed that pharmacological blockade of Pyk2 impairs the ability of PMN to adhere with activated platelets, indicating that Pyk2 may mediate Mac-1 activation during platelet-PMN interaction 22 . The present results showing that Pyk-2 phosphorylation is inhibited by soya isoflavones suggest that Pyk2 may be a novel candidate target to explain the effects of these compounds on PMN adhesive behaviour. Interestingly, Pyk2 appears to be an important mediator of activation and function NADPH complex 21 in adherent PMN. Thus, Pyk2 blockade might also explain the inhibitory effects of isoflavones on superoxide anion production.
In summary, the present study offers new experimental support to the biological plausibility of the epidemiological finding that soya consumption decreases CVD morbidity and mortality 39 . The beneficial effect of soya food might be linked to the biological properties of isoflavones. In addition to being antioxidant and platelet inhibitors, these compounds also appeared to significantly reduce potential mechanisms of vascular ischaemic disease, such as PMN activation and platelet-PMN interaction.
Although evidence for the beneficial effects of soya isoflavones is increasing, further studies are needed. Controlled, randomized clinical trials are necessary to determine their safety and identify the population(s) who can benefit most from the use of these compounds.
